Premium
Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: Pilot study
Author(s) -
Kornberg Arno,
Küpper Bernadett,
Tannapfel Andrea,
Bärthel Erik,
Thrum Katharina,
Settmacher Utz
Publication year - 2007
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2006.04516.x
Subject(s) - medicine , ribavirin , hepatitis c , liver transplantation , antiviral treatment , virology , interferon , transplantation , antiviral therapy , immunology , viral disease , hepatitis c virus , gastroenterology , chronic hepatitis , human immunodeficiency virus (hiv) , virus
Background: The aim of this pilot study was to evaluate efficacy of a long‐term antiviral maintenance therapy (AMT) with interferon‐α2b and ribavirin in liver transplant recipients with recurrent hepatitis C. Methods: Twenty‐one patients with recurrent hepatitis C after liver transplantation received AMT with interferon and ribavirin, following 12 months of a basic antiviral combination treatment. Allograft function, viremia loads and allograft morphology were evaluated continuously. Results: After 12 months of basic antiviral therapy, 14 patients (66.6%) had achieved initial clearance of viremia levels, and 17 recipients (81%) demonstrated normalization of allograft function, respectively. Inflammation score declined significantly (6.0 vs 3.9; P = 0.002), while stage of fibrosis remained unchanged. In virological responders maintenance therapy led to further regression of inflammation score (4.0 at baseline vs 3.1 at 24 months AMT) and fibrosis score (1.6 at baseline vs 1.1 at 24 months AMT). Despite persistence of viremia levels, continued antiviral therapy prevented progression to severe allograft inflammation in virological non‐responders. Hematologic adverse effects resulted in treatment discontinuation in seven patients (33.3%). Conclusion: Long‐term AMT, if tolerable, might be an effective approach for preventing progression to severe allograft fibrosis and thereby improving long‐term survival in liver transplant recipients with recurrent hepatitis C.